SCLX logo

SCILEX HOLDING CO

SCLXNASDAQ
🏆 #4714 by market capUS Equity
$2.09▲ $0.05 (+2.21%)
Pre-market · at close
🔔
Track SCLX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.2%
7d▼ 15.2%
14d▼ 26.3%
30d▼ 57.2%
ytd▼ 83.1%
1y▼ 88.4%
🏦Market Cap
$15M
Small Cap
📈Revenue Growth (YoY)
-46.5%
Declining
📊Gross Margin
41.5%
Healthy
💵FCF Margin
-56.7%
Thin
⚖️P/S Ratio
0.5x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$2.04 – $2.09
52-Week Range
$2.01 – $27.00
Volume (shares)
500
Avg Volume (shares)
—
Shares Outstanding
7.0M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$30M
Last Q Revenue
$8M
P/E Ratio
-0.0
P/S Ratio
0.5x
EPS (TTM)
$-64.87
Dividend Yield
0.00%
Dilution (1yr)
−0.4%
SCLX logo

SCILEX HOLDING CO

SCLX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$30M▼ −46.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
49.7%▼ −29.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$272M▲ +226.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$4M▼ −80.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
6.9M▼ −0.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$128M▼ −$93M YoY
StockOtter · stockotter.space

About SCILEX HOLDING CO

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Aug 2026

Latest News & Updates

News unavailable.